Clinical Research Directory

Inclusion Criteria: * Documented locally advanced head and neck malignancies for which concurrent chemoradiation has been recommended for definitive or adjuvant treatment * No history of prior radiotherapy to the head and neck; however, if previous treatment was superficial skin radiotherapy without regional lymph node treatment this will be allowed * Karnofsky performance status (KPS) \>= 70 * Body mass index \>= 18 kg/m\^2 * No evidence of metastatic disease (M1 disease) * No G-tube placement prior to initiation of chemoradiation * Eligible to undergo concurrent chemotherapy as determined by treating medical oncologist * If a woman is of childbearing potential, a negative serum pregnancy test must be documented prior to proceeding with chemoradiation; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for at least 4 weeks after study treatment * Ability to understand and willingness to sign a written informed consent * Able to tolerate the taste of one of the flavors of the oral nutritional supplement Soylent * Able and willing to participate in the Swallow Preservation Program at the Speech Pathology Clinic * No evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation Exclusion Criteria: * Patients who have previously received therapeutic radiation therapy to the head and neck except for superficial skin radiotherapy is allowed * Patients who had G-tube placement due to concern for aspiration or due to severe malnutrition in advance of chemoradiation * Patients underweight in advance of chemoradiation (BMI \< 18 kg/m\^2) * Patients who refuse to use Soylent oral nutritional supplementation due to its taste or other patient preference reasons * Patients with allergies to any of the ingredients contained in the nutritional supplement * Pregnant women, or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception for the entire study period and for up to 4 weeks after the study treatment * Refusal to sign the informed consent * Refusal to participate in the Swallow Preservation Program prior to start of Soylent if applicable * Evidence of clinically significant swallowing dysfunction by history or physical exam at time of radiation oncology consultation * Distant metastatic disease (M1 disease)